TopFunds

Incyte

NASDAQ: INCY

Stock price

112.75 USD

(+0%) TODAY

Biotechnology
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
-
0.5
(1.5)
0.5
2.1
(1.4)
4.3
1.5
2.7
0.2
6.4
71%
02Free cash flow per share
0.3
1
(1)
1.2
2.9
(1.4)
2.6
4
2
1.2
6.7
35.5%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
753.8
1,106
1,536
1,882
2,159
2,667
2,986
3,395
3,696
4,241
5,141
21.2%
06% Change
-
-
-
-
-
-
-
-
-
-
-
21.2%
07Cost of revenue
(27)
(58.2)
(79.5)
(94.1)
(114.2)
(131.3)
(151)
(207)
(255)
(312.1)
(372.1)
30%
08Gross profit
726.8
1,048
1,457
1,788
2,045
2,535
2,835
3,188
3,441
3,929
4,769
20.7%
09% Margin
96.4%
94.7%
94.8%
95%
94.7%
95.1%
94.9%
93.9%
93.1%
92.6%
92.8%
94.4% A
10Operating expenses
(676.1)
(902.5)
(1,700)
(1,659)
(1,643)
(2,799)
(2,250)
(2,596)
(2,785)
(3,828)
(3,426)
17.6%
11% of Revenue
(89.7)%
(81.6)%
(110.7)%
(88.1)%
(76.1)%
(105)%
(75.3)%
(76.5)%
(75.4)%
(90.3)%
(66.6)%
(85)% A
12Operating Income
50.7
145
(243.4)
129.2
402
(263.7)
585.8
591.6
655.4
101.3
1,343
38.8%
13Income tax expense
(1)
(3.2)
(0.9)
(5.9)
(39.9)
(63.5)
(378.1)
(188.5)
(236.6)
(284)
(377.8)
80.6%
14Net Income
6.5
104.2
(313.1)
109.5
446.9
(295.7)
948.6
340.7
597.6
32.6
1,287
69.6%
15% Margin
0.9%
9.4%
(20.4)%
5.8%
20.7%
(11.1)%
31.8%
10%
16.2%
0.8%
25%
8.1% A
16Shares Outstanding
187.3
194.1
204.6
215.6
217.7
218.1
222.1
224
225.9
210.5
200.7
0.7%
17EPS Basic
-
0.6
(1.5)
0.5
2.1
(1.4)
4.3
1.5
2.7
0.2
6.6
66.6%
18EPS Diluted
-
0.5
(1.5)
0.5
2.1
(1.4)
4.3
1.5
2.7
0.2
6.4
71%
19EBITDA
98
204.6
(253.2)
171.9
543.2
(178.2)
630.2
599.6
919.4
408.2
1,760
33.5%
% Margin
13%
18.5%
(16.5)%
9.1%
25.2%
(6.7)%
21.1%
17.7%
24.9%
9.6%
34.2%
13.7% A
20Net Interest Income (expense)
(40.3)
(34.1)
(6.9)
(1.5)
(1.9)
(2.2)
(1.9)
(2.7)
(2.6)
126.4
103.2
-
21Net Debt / EBITDA
1
-
3.5
(6.6)
(3.3)
8.2
(3.2)
(4.9)
(3.5)
(4)
(1.7)
(1.3) A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
521.4
652.3
899.5
1,164
1,833
1,513
2,057
2,951
3,213
1,688
3,098
19.5%
23Short-term investments
186.3
156.2
270.1
274.3
284.9
288.4
290.8
287.5
442.7
470.3
482.8
10%
24Accounts receivable
114.5
148.8
266.3
307.6
308.8
482
616.3
644.9
743.6
853.2
1,024
24.5%
25Other current assets
17.8
32.8
62.4
79.4
43.7
60.1
126.3
167
182.8
168.9
317.8
33.4%
26Inventory
1.8
4.1
6.5
7
11.4
16.4
27.9
42
63
58.9
101.1
49.7%
27Total Current Assets
842.4
994.2
1,505
1,832
2,482
2,360
3,119
4,093
4,645
3,239
5,024
19.6%
Non-Current Assets
28Net property, plant & equipment
86
167.7
259.8
319.8
406.6
588.1
751.5
765.6
777
794.2
758.4
24.3%
29Long-term investments
35.2
32
134.4
99.2
133.7
222.3
221.3
133.7
187.7
18.8
48
3.1%
30Other non-current assets
43.8
444.8
403.6
394.6
405
390.6
841.9
848.9
1,172
1,392
717.4
32.3%
31Total Non-Current Assets
165.1
644.4
797.7
813.5
945.3
1,201
1,815
1,748
2,137
2,205
1,524
24.9%
Total Assets
1,007
1,639
2,303
2,646
3,427
3,561
4,933
5,841
6,782
5,444
6,958
21.3%
LIABILITIES
Current Liabilities
32Accounts payable
30.1
75.6
67.7
103.8
83.6
98.8
172.1
277.5
109.6
197.5
209.9
21.4%
33Short-term debt
-
-
7.4
18.7
28.3
15
13.2
11.4
9.1
10
10.2
4.1%
34Other current liabilities
137.9
197.9
300.3
302.8
401.4
517.5
669
868.2
1,122
1,434
1,295
25.1%
35Total Current Liabilities
168
273.5
375.4
425.3
513.3
631.2
854.3
1,157
1,240
1,642
1,515
24.6%
Non-Current Liabilities
36Long-term debt
619.9
651.5
16.6
17.4
31.9
32.6
31.6
30.1
29.2
33.5
59.2
(20.9)%
37Other non-current liabilities
48.4
294.1
279.9
277.1
283.1
285.9
277.4
283.7
322.7
321.3
229
16.8%
38Total Non-Current Liabilities
668.3
945.6
296.6
294.5
315
318.5
309
313.8
351.9
354.8
288.2
(8.1)%
39Total Liabilities
836.3
1,219
672
719.8
828.3
949.7
1,163
1,471
1,592
1,997
1,803
8%
SHAREHOLDERS` EQUITY
40Common stock
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.6%
41Retained earnings / (deficit)
(1,779)
(1,675)
(1,990)
(1,878)
(1,431)
(1,727)
(777.9)
(437.2)
160.4
(1,073)
213.8
-
42Accumulated other comprehensive income / (loss)
(0.8)
(2.9)
(7)
(10.2)
(15.5)
(15.4)
(19.5)
15.1
13.1
(13.1)
25.5
-
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
171.2
419.5
1,631
1,926
2,598
2,611
3,770
4,370
5,190
3,448
5,168
40.6%
45Total Liabilities and shareholders' Equity
1,007
1,639
2,303
2,646
3,427
3,561
4,933
5,841
6,782
5,444
6,958
21.3%
46Total Debt
619.9
651.5
24
36.1
60.2
47.5
44.8
41.5
38.3
43.5
69.4
(19.7)%
47Net Debt
98.5
(0.9)
(875.5)
(1,128)
(1,773)
(1,466)
(2,013)
(2,910)
(3,175)
(1,644)
(3,028)
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
6.5
104.2
(313.1)
109.5
446.9
(295.7)
948.6
340.7
597.6
32.6
1,287
69.6%
49Depreciation & amortization
44.9
58.4
52.2
55
54.5
51.8
57.8
67.9
82.7
89.2
93.3
7.6%
50Share-based compensation expense
69.9
96.2
133.1
148.2
166.6
177.9
183
188.4
215.9
266.1
249.3
13.6%
51Changes in working capital and other assets
(34.7)
45.9
34.9
23.6
42.6
(58.6)
(439.9)
373
(399.7)
(52.6)
(215.8)
20%
52Net cash flows from operating activities
86.5
304.8
(93)
336.2
710.7
(124.6)
749.5
969.9
496.5
335.3
1,414
32.2%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(26)
(120.3)
(111)
(73.5)
(78.1)
(187.4)
(181)
(77.8)
(47.5)
(86.3)
(58.9)
8.5%
54Purchases of investments / marketable securities
(148)
(57.4)
(384.7)
(168.9)
(374.8)
(612.3)
(268.7)
(79.9)
(466)
(258.4)
(303.4)
7.4%
55Proceeds from maturities of marketable securities
69
88
145.7
155.9
365.4
530.7
242
79.2
305.8
516.1
284.6
15.2%
56Other investing activities
-
(142.9)
-
-
-
-
-
-
-
(13.9)
(25)
(17.6)%
57Net cash flows from investing activities
(105)
(232.5)
(350)
(86.4)
(87.5)
(269)
(207.7)
(78.5)
(207.7)
157.5
(102.6)
(0.2)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
86.4
50
649.4
29.9
63.3
110.3
58.6
61.1
35.8
(1,956)
202.7
8.9%
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
(1.7)
(0.4)
-
-
(0.8)
(0.8)
(2.4)
(2.9)
(3.4)
(3.8)
(4.5)
10.3%
61Other financing activities
2.9
9.1
40.8
(15.3)
(16.8)
(37.8)
(50)
(59)
(52.5)
(62.3)
(97.1)
-
62Net cash flows from financing activities
87.6
58.6
690.2
14.7
45.7
71.7
6.2
(0.8)
(20)
(2,022)
101
1.4%
63Increase (decrease) in cash and cash equivalents
69.1
130.9
247.2
264.6
668.7
(318.9)
544.4
894
262.1
(1,526)
1,410
35.2%
64Cash and equivalents, ending balance
521.4
652.3
899.5
1,165
1,834
1,515
2,059
2,953
3,215
1,690
3,100
19.5%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
60.5
184.5
(204)
262.7
632.6
(312)
568.5
892.1
449
249.1
1,355
36.5%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Incyte (INCY) financial statements and performance

Explore Incyte (INCY) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.